Home Search

viaskin peanut - search results

If you're not happy with the results, please do another search
Viaskin Patch

Viaskin Peanut Phase III Trial Falls Short, Still Chance for FDA Approval

0
The Viaskin Peanut patch therapy still has 50:50 chance of approval according to research note.
Viaskin Patch

Viaskin Peanut Patch: Lasting Response After Three Years

0
Pediatric patients responded with a favorable safety profile and no serious adverse effects.

Viaskin Peanut, Milk and Egg Patch Therapies: Promising News from the AAAAI Conference

5
We are cautiously optimistic that a safe, effective, easy to administer treatment for food allergy may be on the horizon.
Viaskin Patch

DBV Announces Positive Regulatory Updates for the Viaskin® Peanut Patch in the United States and...

Company to pursue an Accelerated Approval pathway for toddlers ages 1–3 years-old.
Viaskin Peanut

DBV Announces Promising 2-Year Results from Ongoing Viaskin “Peanut Patch” Toddler Study

81.3% of subjects who completed the oral food challenge reached an eliciting dose of ≥1,000 mg after 24 months of treatment.
Viaskin Patch

Will the Viaskin “Patch” Therapy for Peanut Allergy be Approved Soon? The Company is...

0
Company is restructuring in anticipation of delays.
Viaskin Patch

Viaskin Patch Delivers Long-Lasting Peanut Desensitization After Phase IIb Trial

0
The study was designed to assess the long-term efficacy and safety of the treatment in subjects that had graduated from their earlier VIPES trial.
Viaskin Patch

Viaskin Milk Results Shows Potential for Treatment of Milk Allergy in Children

0
95.5% of the participants completed treatment, with most adverse effects being mild or moderate reactions at the application site.
Viaskin-Patch

FDA Removes Hold Allowing DBV’s Pivotal Phase 3 Peanut Patch Trial to Commence

0
The phase 3 trial of the modified Viaskin Peanut patch has been cleared for commencement.
Viaskin Patch

Skin Patch Immunotherapy Determined Safe and Effective in Toddlers With Peanut Allergy

0
According to research presented at this year's #ACAAI22 meeting.